tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

BIVI Stock Latest News

BioVie secures all scientific approvals needed to receive $12.6M grant funding
The FlyBioVie secures all scientific approvals needed to receive $12.6M grant funding
4d ago
BIVI
BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID
PremiumPress Releases
BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID
4d ago
BIVI
BioVie announces FDA authorization of IND for Phase 2 trial of bezisterim
PremiumThe Fly
BioVie announces FDA authorization of IND for Phase 2 trial of bezisterim
17d ago
BIVI
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID
PremiumPress Releases
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID
17d ago
BIVI
BioVie to give data for epigenetic basis for bezisterim and aging at ARDD 2024
PremiumThe Fly
BioVie to give data for epigenetic basis for bezisterim and aging at ARDD 2024
24d ago
BIVI
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting
PremiumPress ReleasesBioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting
24d ago
BIVI
BioVie achieves alignment with FDA on upcoming SUNRISE-PD trial
Premium
The Fly
BioVie achieves alignment with FDA on upcoming SUNRISE-PD trial
1M ago
BIVI
BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease
Premium
Press Releases
BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease
1M ago
BIVI
BioVie announces 1-for-10 reverse stock split
PremiumThe Fly
BioVie announces 1-for-10 reverse stock split
1M ago
BIVI
BioVie Inc. Announces Reverse Stock Split
PremiumPress Releases
BioVie Inc. Announces Reverse Stock Split
1M ago
BIVI
BioVie Inc. trading halted, news pending
PremiumThe Fly
BioVie Inc. trading halted, news pending
2M ago
BIVI
BioVie Announces Amicable Departure of Board Director Gorlin
PremiumCompany Announcements
BioVie Announces Amicable Departure of Board Director Gorlin
2M ago
8K
BIVI
BioVie initiated with a Buy at ThinkEquity
PremiumThe FlyBioVie initiated with a Buy at ThinkEquity
3M ago
BIVI
BioVie unveils protocol design of SUNRISE-PD Phase 2 trial of NE3107
Premium
The Fly
BioVie unveils protocol design of SUNRISE-PD Phase 2 trial of NE3107
3M ago
BIVI
BioVie presents protocol design for upcoming Phase 2 trial of bezisterim
Premium
The Fly
BioVie presents protocol design for upcoming Phase 2 trial of bezisterim
3M ago
BIVI
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress
PremiumPress Releases
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress
3M ago
BIVI
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26
PremiumPress Releases
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26
3M ago
BIVI
BioVie announces formation of a long COVID Advisory Board
PremiumThe Fly
BioVie announces formation of a long COVID Advisory Board
4M ago
BIVI
BioVie announces data from oral presentation on bezisterim
PremiumThe Fly
BioVie announces data from oral presentation on bezisterim
4M ago
BIVI
BIVI Earnings this Week: How Will it Perform?
PremiumPre-EarningsBIVI Earnings this Week: How Will it Perform?
4M ago
BIVI
BioVie awarded up to $13.1M in funding from U.S. DOD to evaluate bezisterim
Premium
The Fly
BioVie awarded up to $13.1M in funding from U.S. DOD to evaluate bezisterim
5M ago
BIVI
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
Premium
Press Releases
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
5M ago
BIVI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >